Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.940
+0.050 (1.02%)
May 20, 2026, 9:43 AM EDT - Market open
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
53
Market Cap
319.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIMRX News
- 4 days ago - Immuneering reports Q1 EPS (21c), consensus (25c) - TheFly
- 5 days ago - Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 days ago - Immuneering Earnings release: Q1 2026 - Filings
- 5 days ago - Immuneering Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Immuneering announces updated data from Phase 2a trial for atebimetinib - TheFly
- 4 weeks ago - Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 4 weeks ago - Immuneering announces presentation of new genetic data at 2026 AACR - TheFly
- 4 weeks ago - Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond - GlobeNewsWire